Rejeeve Biotech (688068.SH) controlled subsidiary Shunjing Pharmaceuticals has obtained the "Specialized, Specialized, and Innovative" Small and Medium-sized Enterprise Certificate from the Beijing Municipal Government.

Zhito Financal APP News, Rejing Bio (688068.SH) announced that recently, the company's holding subsidiary, Beijing Shunjing Biomedical Technology Co., Ltd. (referred to as "Shunjing Medicine"), has received a certificate issued by the Beijing Municipal Bureau of Economy and Information Technology. Shunjing Medicine has been recognized as a "specialized, innovative and small" enterprise in Beijing, with a validity period from April 2026 to April 2029.